Rapid characterization of drug-drug interaction in plasma protein binding using a surface plasmon resonance biosensor

被引:11
作者
Kuroda, Yukihiro [1 ,2 ]
Saito, Madoka [1 ]
Sakai, Harumi [2 ]
Yamaoka, Takashi [2 ]
机构
[1] Mukogawa Womens Univ, Sch Pharmaceut Sci, Nishinomiya, Hyogo 6638179, Japan
[2] Sumika Chem Anal Serv Ltd, Analyt Biotechnol Ctr, Osaka, Japan
关键词
surface plasmon resonance; high-throughput screening; drug-drug interaction; human serum albumin; plasma protein binding;
D O I
10.2133/dmpk.23.120
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
High-throughput characterization of drug-drug interactions in plasma protein binding was demonstrated by using a surface plasmon resonance (SPR) biosensor. The method used in this study enabled the discrimination between the two modes of binding inhibition, direct competition and negative allosteric effect, which was difficult in conventional SPR approaches. Two theoretical equations were used representing SPR binding response for directly competitive binding or for independent binding. The experimental binding data for human serum albumin was processed by non-linear least squared regression of the equations. By this approach, drug-drug interactions were classified into three modes, direct competition, independent binding, and allosteric interaction, which were almost consistent with previous reports. In addition, dissociation constants were also estimated roughly for direct competition and for independent binding. The analytical throughput was almost as high as in the previous reports; three minutes per injection. This method is a powerful tool for the characterization of drug-drug interaction at an early stage of new drug development.
引用
收藏
页码:120 / 127
页数:8
相关论文
共 17 条
[1]   Development of tryptophan-modified human serum albumin columns for site-specific studies of drug-protein interactions by high-performance affinity chromatography [J].
Chattopadhyay, A ;
Tian, T ;
Kortum, L ;
Hage, DS .
JOURNAL OF CHROMATOGRAPHY B, 1998, 715 (01) :183-190
[2]   Quantitative analysis of allosteric drug-protein binding by biointeraction chromatography [J].
Chen, JZ ;
Hage, DS .
NATURE BIOTECHNOLOGY, 2004, 22 (11) :1445-1448
[3]   Characterizing a drug's primary binding site on albumin [J].
Day, YSN ;
Myszka, DG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (02) :333-343
[4]   A GENERAL, WIDE-RANGE SPECTROFLUOROMETRIC METHOD FOR MEASURING THE SITE-SPECIFIC AFFINITIES OF DRUGS TOWARD HUMAN SERUM-ALBUMIN [J].
EPPS, DE ;
RAUB, TJ ;
KEZDY, FJ .
ANALYTICAL BIOCHEMISTRY, 1995, 227 (02) :342-350
[5]  
FETTER J, 1998, J PROTEIN CHEM, V17, P115
[6]  
Fitos I, 1999, CHIRALITY, V11, P115, DOI 10.1002/(SICI)1520-636X(1999)11:2<115::AID-CHIR6>3.0.CO
[7]  
2-R
[8]   Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels [J].
Frostell-Karlsson, Å ;
Remaeus, A ;
Roos, H ;
Andersson, K ;
Borg, P ;
Hämäläinen, M ;
Karlsson, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (10) :1986-1992